Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis

NCT06477237 is registered in ClinicalTrials.gov with Huabo Biopharm Co., Ltd. as lead sponsor.

NCT NCT06477237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06477237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
Lead sponsor
Huabo Biopharm Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2024
Completion date
December 31, 2025
Enrollment
400 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis